Four Aspects Affecting Health Economic Decision Models and Their Validation-Reference-Cited by-同舟云学术

Four Aspects Affecting Health Economic Decision Models and Their Validation

Published:2021-12-16 Issue: Volume: Page:
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Feenstra Talitha^ORCID,Corro-Ramos Isaac^ORCID,Hamerlijnck Dominique^ORCID,van Voorn George^ORCID,Ghabri Salah

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40273-021-01110-w.pdf

Reference55 articles.

1. Barendregt JJ, Bonneux L. The trouble with health economics. Eur J Public Health. 1999;9(Part 4):309–12.

2. Miller JD, Foley KA, Russell MW. Current challenges in health economic modeling of cancer therapies: a research inquiry. Am Health Drug Benefits. 2014;7(3):153–62.

3. Langley PC. Another imaginary world: the ICER claims for the long-term cost-effectiveness and pricing of vesicular monoamine transporter 2 (VMAT2) inhibitors in tardive dyskinesia. Innov Pharm. 2017;8(4):12.

4. Asche CV, Hippler SE, Eurich DT. Review of models used in economic analyses of new oral treatments for type 2 diabetes mellitus. Pharmacoeconomics. 2014;32(1):15–27.

5. Ghabri S, Binard A, Pers YM, Maunoury F, Caro JJ. Economic evaluation of sequences of biological treatments for patients with moderate-to-severe rheumatoid arthritis and inadequate response or intolerance to methotrexate in France. Value Health. 2020;23(4):461–70.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Validating Health Economic Models With the Probabilistic Analysis Check dashBOARD;Value in Health;2024-08

2. Open-economy macroeconomics with financial frictions: A simple model with flexible exchange rates;Journal of Financial Stability;2024-08

3. Use of Adjuvanted Quadrivalent Influenza Vaccine in Older-Age Adults: A Systematic Review of Economic Evidence;Vaccines;2024-05-10

4. Barriers and Facilitators of Using R for Decision Analytic Modeling in Health Technology Assessment: Focus Group Results;PharmacoEconomics;2024-04-12

5. Evaluating the Validation Process: Embracing Complexity and Transparency in Health Economic Modelling;PharmacoEconomics;2024-03-18